More about ADSTILADRIN®

What is ADSTILADRIN?

ADSTILADRIN (nadofaragene firadenovec-vncg) was approved in the United States in 2022 and is fully available for appropriate patients as a treatment that may help people live better lives on their bladder cancer journey.

ADSTILADRIN is a localized gene therapy designed to help the immune system fight NMIBC directly within the bladder. Administered once every 3 months, it works as a monotherapy, meaning it does not require combination with other medications to be effective. ADSTILADRIN is not chemotherapy or Bacillus Calmette-Guérin (BCG) treatment and does not require coadministration with BCG. It is an intravesical treatment option that may help preserve the bladder when BCG fails. It targets the cancer within the bladder without impacting the entire body, potentially reducing side effects. Importantly, it does not alter your genes; instead, it works with your immune system to stop the growth of cancer cells and destroy them. ADSTILADRIN is also designed for convenience, as it can be administered by your urologist in their office, allowing you to continue treatment with your current doctor.

For ADSTILADRIN patients, Ferring offers an excellent support mechanism in the Ferring Patient Assistance Program, which can even help determine how to navigate the financial aspects of bladder cancer treatment and survivorship. This program also offers patient assistance, coverage support, and other valuable resources for eligible uninsured/underinsured patients, including referrals to third-party organizations including 501(c)(3) charities, patient support and education groups, and state health exchange resources. Additionally, it offers help with scheduling appointments and staying on top of your treatment journey. It is as simple as enrolling, getting support, and staying supported.

STIL effective out to 5 years

At 3 months: More than half of the people who received instillations of ADSTILADRIN had a complete response (with no signs of high-grade bladder cancer) after just 1 dose (n=50).

At 1 year: 73% of people were estimated to keep their bladder Out to 5 years: Of the people who received at least 1 dose of ADSTILADRIN, nearly half were estimated to keep their bladder and 96% of people did not progress to muscle-invasive bladder cancer, even if their cancer didn’t go away completely (based on results from a transurethral resection of bladder tumors; n=103/107).

ADSTILADRIN upholds the commitment to helping people with bladder cancer live better lives by bringing science to life. This holds true for people like Mike, an actual ADSTILADRIN patient. Before ADSTILADRIN, Mike was already on his own bladder cancer journey, starting with his diagnosis.